azurrx
biopharma
provides
insight
drawbacks
using
porcine
products
production
pharmaceuticals
medicinals
offers
update
efforts
produce
synthetic
alternatives
new
york
globe
newswire
via
investorwire
azurrx
biopharma
nasdaq
azrx
azurrx
company
new
biopharmaceutical
company
specializing
development
therapeutic
proteins
treatment
patients
gastrointestinal
disorders
today
provides
insight
usage
porcine
products
producing
pharmaceuticals
medicinals
inherent
downsides
associated
usage
well
updates
regarding
efforts
develop
synthetic
alternatives
porcine
ingredients
pigs
used
medical
research
centuries
used
general
surgical
models
dermatological
studies
involving
wound
healing
plastic
surgery
procedures
toxicology
pharmacology
studies
transplantation
studies
among
areas
research
also
used
nearly
medications
pharmaceuticals
according
information
pork
industry
including
six
pancreas
however
supply
chain
concentration
purity
issues
arising
using
porcine
ingredients
treat
problems
related
pancreas
malfunction
due
issues
azurrx
among
several
companies
working
develop
synthetic
products
replace
porcine
ingredients
wherever
possible
one
promising
therapy
azurrx
developed
lead
product
candidate
recombinant
lipase
studied
treatment
exocrine
pancreatic
insufficiency
epi
associated
cystic
fibrosis
cf
chronic
pancreatitis
cp
azurrx
pursuing
parallel
clinical
pathways
phase
monotherapy
clinical
trial
phase
combination
therapy
trial
pancreas
medications
help
replace
enzymes
pancreas
longer
produce
due
cystic
fibrosis
pancreatitis
pancreatic
cancer
causes
currently
patients
required
take
many
tablets
per
day
depending
symptoms
according
organization
economic
development
top
hog
producers
world
produced
metric
tons
hogs
total
production
china
accounted
metric
tons
percent
producer
metric
tons
obvious
data
china
far
greatest
supplier
porcine
products
pharmaceutical
medicinal
therapies
china
dominance
area
grown
several
issues
raised
regarding
supply
line
availability
product
impurities
enzyme
variability
swine
flu
diseases
severely
cut
production
causing
supply
chain
issues
chinese
ministry
agriculture
rural
affairs
reported
china
hog
herd
declined
october
percent
year
earlier
additionally
according
new
york
times
also
reports
wide
variations
enzyme
concentrations
pills
derived
pork
sold
several
companies
leslie
hendeles
florida
professor
said
clear
much
disparity
attributable
variations
pig
pancreases
industry
technique
called
overfill
extra
ingredients
added
capsules
lose
potency
expiration
dates
according
new
york
times
article
history
unusual
variations
impurities
pills
led
cystic
fibrosis
foundation
pursue
alternative
history
shown
risk
transmitting
disease
drugs
small
merely
theoretical
according
paul
brown
retired
national
institutes
health
senior
investigator
time
take
tissue
extract
process
tissue
one
species
put
another
species
even
another
animal
run
risk
unwanted
pathogens
know
responsible
repeated
problems
course
time
brown
said
something
without
taking
tissue
product
another
ahead
august
azurrx
announced
positive
results
first
five
patients
phase
combination
therapy
trial
treatment
severe
exocrine
pancreatic
insufficiency
epi
patients
cystic
fibrosis
cf
primary
efficacy
analysis
patients
receiving
combination
pert
therapy
achieved
clinically
meaningful
improvement
coefficient
fat
absorption
cfa
three
dose
levels
adverse
safety
events
reported
additionally
patients
showed
improvements
key
secondary
endpoints
including
body
weight
stool
consistency
reductions
number
bowel
movements
incidence
steatorrhea
october
company
announced
activated
two
trial
sites
turkey
phase
combination
therapy
clinical
trial
investigate
cystic
fibrosis
cf
patients
severe
exocrine
pancreatic
insufficiency
epi
total
eight
expected
sites
europe
active
recruiting
patients
truly
pleased
encouraged
interest
expanding
global
phase
combination
trial
said
james
pennington
chief
medical
officer
azurrx
recently
reported
interim
data
suggests
promising
results
full
data
readout
expected
second
quarter
next
year
investigators
turkey
extremely
diligent
driving
startup
trial
efficient
effective
manner
look
forward
continued
work
azurrx
biopharma
azurrx
biopharma
nasdaq
azrx
biopharmaceutical
company
specializing
research
development
biologics
gastrointestinal
disorders
company
focused
development
lead
drug
candidate
azurrx
currently
conducting
two
phase
clinical
trials
option
monotherapy
trial
combination
therapy
trial
consisting
conjunction
pancreatic
enzyme
replacement
therapy
current
standard
care
company
headquartered
new
york
new
york
clinical
operations
hayward
california
additional
information
company
found
request
additional
information
ongoing
updates
statements
press
release
may
contain
certain
statements
relating
future
results
statements
statements
historical
facts
instead
represent
company
belief
regarding
future
events
many
nature
inherently
uncertain
outside
company
control
possible
company
actual
results
financial
condition
may
differ
possibly
materially
anticipated
results
financial
condition
indicated
statements
additional
information
concerning
company
business
including
discussion
factors
could
materially
affect
company
financial
results
including
related
clinical
development
results
clinical
trials
impact
coronavirus
pandemic
company
operations
current
planned
clinical
trials
including
limited
delays
clinical
trial
recruitment
participation
contained
company
annual
report
form
year
ended
dec
heading
risk
factors
well
company
subsequent
filings
securities
exchange
commission
statements
included
press
release
made
date
press
release
undertake
obligation
publicly
update
correct
statements
reflect
events
circumstances
subsequently
occur
hereafter
become
aware
corporate
communications
investorbrandnetwork
ibn
los
angeles
california
office
editor
investor
relations
lifesci
advisors
llc
hans
vitzthum
hans
boston
massachusetts
office
